Intranasal Dexmedetomidine: Efficacy and Safety as a Single Agent for Noninvasive Interventions among Pediatric Patients

Abstract

Intranasal dexmedetomidine has become increasingly utilized for pediatric patients. The purpose of this work is to evaluate the efficacy and safety of intranasal dexmedetomidine, as a monotherapy and administered by pediatric intensivists, for a variety of interventions among pediatric patients, as there are limited studies describing this in the literature. This was a retrospective analysis of pediatric patients (outpatient, inpatient floor, and critical care statuses) undergoing noninvasive interventions between July 5, 2017 and July 5, 2022. The primary outcome of interest was the type and number of adverse events (respiratory, cardiovascular, neurological, and patient intolerance events). The secondary outcome was the length of sedation. Additional data of interest included age, length of recovery, and type of intervention. There were 59 sedations completed using intranasal dexmedetomidine as a single agent. No adverse events were observed. The median age of patients was 14 months (interquartile range [IQR]: 8.50–26.50 months). The median sedation time was 69 minutes (IQR: 57.5–87.5) and 75% of the patients recovered within 43 minutes. The majority of patients (54%) underwent computed tomography scans, but additional interventions ranged from auditory brainstem response evaluations to echocardiograms. Intranasal dexmedetomidine seems to be a safe and effective monotherapy for noninvasive interventions in the pediatric population and can be administered by pediatric intensivists.

Keywords

dexmedetomidine - sedation - pediatric - intranasal

Publikationsverlauf

Eingereicht: 20. August 2024

Angenommen: 30. Oktober 2024

Artikel online veröffentlicht:
26. Dezember 2024

• References

• 1 Han G, Yu WW, Zhao P. A randomized study of intranasal vs. intravenous infusion of dexmedetomidine in gastroscopy. Int J Clin Pharmacol Ther 2014; 52 (09) 756-761
• 2 Kg K. N P. Intranasal dexmedetomidine with intravenous midazolam: a safe and effective alternative in pediatric MRI sedation. Cureus 2023; 15 (10) e46787
• 3 Phan H, Nahata MC. Clinical uses of dexmedetomidine in pediatric patients. Paediatr Drugs 2008; 10 (01) 49-69
• 4 Tsze DS. Intranasal dexmedetomidine: Should it have a place in your emergency department?. Ann Emerg Med 2023; 82 (02) 191-193
• 5 Wolfe TR, Braude DA. Intranasal medication delivery for children: a brief review and update. Pediatrics 2010; 126 (03) 532-537
• 6 Sury M, Bullock I, Rabar S, Demott K. Guideline Development Group. Sedation for diagnostic and therapeutic procedures in children and young people: summary of NICE guidance. BMJ 2010; 341: c6819
• 7 Miller JW, Balyan R, Dong M. et al. Does intranasal dexmedetomidine provide adequate plasma concentrations for sedation in children: a pharmacokinetic study. Br J Anaesth 2018; 120 (05) 1056-1065
• 8 Uusalo P, Guillaume S, Siren S. et al. Pharmacokinetics and sedative effects of intranasal dexmedetomidine in ambulatory pediatric patients. Anesth Analg 2020; 130 (04) 949-957
• 9 Miller JW, Divanovic AA, Hossain MM, Mahmoud MA, Loepke AW. Dosing and efficacy of intranasal dexmedetomidine sedation for pediatric transthoracic echocardiography: a retrospective study. Can J Anaesth 2016; 63 (07) 834-841
• 10 Miller JW, Ding L, Gunter JB. et al. Comparison of intranasal dexmedetomidine and oral pentobarbital sedation for transthoracic echocardiography in infants and toddlers: a prospective, randomized, double-blind trial. Anesth Analg 2018; 126 (06) 2009-2016
• 11 Li BL, Ni J, Huang JX, Zhang N, Song XR, Yuen VM. Intranasal dexmedetomidine for sedation in children undergoing transthoracic echocardiography study–a prospective observational study. Paediatr Anaesth 2015; 25 (09) 891-896
• 12 Olgun G, Ali MH. Use of intranasal dexmedetomidine as a solo sedative for MRI of infants. Hosp Pediatr 2018; 8: 68-71
• 13 Behrle N, Birisci E, Anderson J, Schroeder S, Dalabih A. Intranasal Dexmedetomidine as a sedative for pediatric procedural sedation. J Pediatr Pharmacol Ther 2017; 22 (01) 4-8